Outcomes and prognostic factors of patients with Extranodal NK T cell lymphoma (ENKTL)

• Published in: Leukemia & lymphoma 2023-12, Vol.64 (12), p.1914-1926
• Main Authors: Rajendra, Akhil, Sengar, Manju, Bonda, V N Avinash, Jain, Hasmukh, Nayak, Lingaraj, Thorat, Jayashree, Shet, Tanuja, Epari, Sridhar, Laskar, Siddharth, Aggarwal, Archi, Rangarajan, V, Gujral, Sumeet, Bagal, Bhausaheb, Kakoti, Sangeeta, Salvi, Omkar
• Format: Article
• Language: English
• Subjects: Antineoplastic Combined Chemotherapy Protocols - therapeutic use; Asparaginase - therapeutic use; Humans; Lymphoma, Extranodal NK-T-Cell - drug therapy; Lymphoma, Extranodal NK-T-Cell - therapy; Neoplasm Recurrence, Local - drug therapy; Prognosis; Retrospective Studies
• ISSN: 1042-8194; 1029-2403
• DOI: 10.1080/10428194.2023.2244101

The staging, prognostication, and treatment of ENKTL has evolved over the years with better understanding of the disease biology. There is significant heterogeneity in the treatment followed across the world. Literature from India have been few with small number of patients. We studied the outcomes and prognostic factors of patients with ENKTL treated between May 2010 and December 2021 at our center. A total of 78 patients diagnosed with ENKTL were treated at our center. L-asparaginase based chemotherapy was administered in 84% of the patients. Close to 2/3 patients received SMILE chemotherapy. After a median follow-up of 30 months (18.5-41.4 months), the median relapse free survival and overall survival for the overall population was 45 months (12-118 months) and 45 months (14-118 months) respectively. By multivariate analysis, PINK score of 2-4, non-receipt of RT and non-achievement of CR were associated with poor survival.